CVRx beats Q3 revenue expectations, gross margin climbs

Reuters11-06

CVRx beats Q3 revenue expectations, gross margin climbs

Overview

CVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectations
U.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awareness
Gross margin rises to 87% in Q3 2025 due to higher selling prices, efficiencies

Outlook

CVRx expects full-year 2025 revenue between $55.6 mln and $56.6 mln
Company forecasts Q4 2025 revenue between $15.0 mln and $16.0 mln
CVRx raises full-year 2025 gross margin guidance to 85%-86%

Result Drivers

U.S. GROWTH - Expansion into new sales territories and increased Barostim awareness drove 10% revenue growth in the U.S.
IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 250, supporting higher implant volumes

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$14.69 mln	$14.20 mln (7 Analysts)
Q3 EPS		-$0.49
Q3 Net Income		-$12.87 mln
Q3 Gross Margin		87.00%
Q3 Basic EPS		-$0.49
Q3 Gross Profit		$12.75 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for CVRx Inc is $12.00, about 16.8% above its November 4 closing price of $9.99

Press Release: ID:nGNX85Lwz5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581083759?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 06:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581083759","market":"nz","top_or_hot":-1,"title":"CVRx beats Q3 revenue expectations, gross margin climbs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CVRx beats Q3 revenue expectations, gross margin climbs</title></head><body><p><span>Overview</span></p><ul><li><p>CVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectations</p></li><li><p>U.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awareness</p></li><li><p>Gross margin rises to 87% in Q3 2025 due to higher selling prices, efficiencies</p></li></ul><p><span>Outlook</span></p><ul><li><p>CVRx expects full-year 2025 revenue between $55.6 mln and $56.6 mln</p></li><li><p>Company forecasts Q4 2025 revenue between $15.0 mln and $16.0 mln</p></li><li><p>CVRx raises full-year 2025 gross margin guidance to 85%-86%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. GROWTH - Expansion into new sales territories and increased Barostim awareness drove 10% revenue growth in the U.S.</p></li><li><p>IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 250, supporting higher implant volumes</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$14.69 mln</p></td><td><p>$14.20 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.49</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.87 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>87.00%</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.49</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$12.75 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CVRx Inc is $12.00, about 16.8% above its November 4 closing price of $9.99</p></li></ul><p>Press Release: <span>ID:nGNX85Lwz5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx beats Q3 revenue expectations, gross margin climbs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx beats Q3 revenue expectations, gross margin climbs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 06:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CVRx beats Q3 revenue expectations, gross margin climbs</title></head><body><p><span>Overview</span></p><ul><li><p>CVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectations</p></li><li><p>U.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awareness</p></li><li><p>Gross margin rises to 87% in Q3 2025 due to higher selling prices, efficiencies</p></li></ul><p><span>Outlook</span></p><ul><li><p>CVRx expects full-year 2025 revenue between $55.6 mln and $56.6 mln</p></li><li><p>Company forecasts Q4 2025 revenue between $15.0 mln and $16.0 mln</p></li><li><p>CVRx raises full-year 2025 gross margin guidance to 85%-86%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. GROWTH - Expansion into new sales territories and increased Barostim awareness drove 10% revenue growth in the U.S.</p></li><li><p>IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 250, supporting higher implant volumes</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$14.69 mln</p></td><td><p>$14.20 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.49</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.87 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>87.00%</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.49</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$12.75 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CVRx Inc is $12.00, about 16.8% above its November 4 closing price of $9.99</p></li></ul><p>Press Release: <span>ID:nGNX85Lwz5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1GQ:1","article_id":"2581083759","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581083759","pubTimestamp":1762382171,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CVRx beats Q3 revenue expectations, gross margin climbsOverviewCVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectationsU.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","CVRX":"CVRx, Inc.","BK4082":"医疗保健设备"},"translate_title":"CVRx第三季度收入超出预期，毛利率攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVRX":0.9},"content_text":"CVRx beats Q3 revenue expectations, gross margin climbsOverviewCVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectationsU.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awarenessGross margin rises to 87% in Q3 2025 due to higher selling prices, efficienciesOutlookCVRx expects full-year 2025 revenue between $55.6 mln and $56.6 mlnCompany forecasts Q4 2025 revenue between $15.0 mln and $16.0 mlnCVRx raises full-year 2025 gross margin guidance to 85%-86%Result DriversU.S. GROWTH - Expansion into new sales territories and increased Barostim awareness drove 10% revenue growth in the U.S.IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 250, supporting higher implant volumesKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$14.69 mln$14.20 mln (7 Analysts)Q3 EPS-$0.49Q3 Net Income-$12.87 mlnQ3 Gross Margin87.00%Q3 Basic EPS-$0.49Q3 Gross Profit$12.75 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for CVRx Inc is $12.00, about 16.8% above its November 4 closing price of $9.99Press Release: ID:nGNX85Lwz5For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581083759","isCrawlerRequest":true}